Abstract
Breast cancer is the second leading cause of cancer‑associated mortalities in women. Tamoxifen (TAM) is an endocrine therapy commonly used in the treatment of patients with breast cancer expressing estrogen receptor α. However, treatment often ends in failure due to the emergence of drug resistance. MicroRNAs (miRNAs), a family of small non‑coding RNAs, serve critical roles in the regulation of gene expression and cell events. To date, whether miRNA‑663b could mediate TAM resistance in breast cancer remains unknown. Therefore, the aim of the present study was to investigate the role of miRNA‑663b in TAM resistance in breast cancer. The results demonstrated that miRNA‑663b was upregulated in breast cancer with TAM resistance. Tumor protein 73 (TP73) was a direct target of miRNA‑663b, and was negatively regulated by miRNA‑663b in MCF‑7 cells. Furthermore, it was identified that downregulation of miRNA‑663b inhibited cell proliferation ability and promoted cell apoptosis, resulting in enhanced TAM sensitivity. In addition, these findings suggested that TP73 silencing may have eliminated the effects of miRNA‑663b inhibitor on breast cancer cells. In conclusion, the present study verified a novel molecular link between miRNA‑663b an...Continue Reading
References
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Feb 23, 2002·Cell Death and Differentiation·I CascianoM Romani
Dec 18, 2004·Cancer Research·Yukun CuiSuzanne A W Fuqua
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Carolina GutierrezMitch Dowsett
May 17, 2005·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Aug 17, 2005·Cancer Research·Marilena V IorioCarlo M Croce
Mar 3, 2006·Genes & Development·Marco Antonio Valencia-SanchezRoy Parker
Aug 3, 2007·The Journal of Clinical Investigation·George A Calin, Carlo M Croce
Jan 24, 2009·Nature Reviews. Molecular Cell Biology·V Narry KimMikiko C Siomi
Jan 27, 2009·Cell·David P Bartel
Dec 22, 2010·Molecular Cancer·Diana M CittellyFrank E Jones
Aug 2, 2011·Lancet·C DaviesR Peto
Oct 1, 2011·Cancer Letters·Tissa T ManavalanCarolyn M Klinge
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·James N Ingle
Dec 19, 2013·Current Opinion in Obstetrics & Gynecology·Nicole Williams, Lyndsay N Harris
Jan 7, 2014·Current Oncology Reports·Stephen R D Johnston, Belinda Yeo
Jan 7, 2014·PloS One·Huafu ZhaoYu Zhang
Apr 23, 2014·The Journal of Pathology·Aoife WardStefan Wiemann
May 28, 2015·Scientific Reports·Mulong DuMeilin Wang
Aug 11, 2015·Scientific Reports·Kazuhiro IkedaSatoshi Inoue
Dec 17, 2015·Molecular Cancer·Xinfeng YuXianjun Qu
May 25, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norman WolmarkSoonmyung Paik
Nov 30, 2016·Oncotarget·Huihua CaiXiaozhou He
May 30, 2017·Acta Pharmacologica Sinica·Ya-Ling WangHai-Yan Hu
Jun 3, 2017·EMBO Molecular Medicine·Marilena V Iorio, Carlo M Croce
Aug 7, 2017·Experimental and Therapeutic Medicine·Shaoqiang LiangTao Xu
Citations
Oct 22, 2020·International Journal of Molecular Sciences·Erik KudelaKamil Biringer
Apr 30, 2021·BMC Cancer·Sevan Omer Majed, Suhad Asad Mustafa
Aug 8, 2021·Cancers·Jéssica Fernanda BarazettiJaqueline Carvalho de Oliveira
Nov 18, 2021·Bioengineered·Fei XieWei Yan